Psychedelics and the neurobiology of meaningfulness

Introduction

Krystal and colleagues frame a tension in psychedelic research between two mechanistic accounts of therapeutic benefit: one emphasises direct neurobiological effects such as enhanced neuroplasticity and synaptogenesis, while the other emphasises the subjective, often profound, experiences users report—particularly a heightened sense of meaningfulness or portentousness. They note that some compounds that lack prominent hallucinatory effects nevertheless produce similar neuroplastic and antidepressant-like changes, which raises the possibility that subjective phenomenology may be irrelevant to therapeutic action. At the same time, many people rate psychedelic experiences among the most important of their lives, and earlier work shows that the degree to which an experience is judged as meaningful or important predicts clinical outcomes across conditions such as depression and addiction. The paper therefore asks whether the capacity of psychedelics to induce a feeling that something important is happening is itself a primary effect that might synergise with circuit- and plasticity-level processes to produce clinical benefit. The authors outline psychological mechanisms by which increased salience or a restored sense of purpose could promote adaptive learning and resilience, and they note that therapeutic insights reported after psychedelic sessions may sometimes reflect therapist-provided frames rather than intrinsic truths revealed by the drug experience. This sets up the central question of the commentary: are experiences of meaningfulness a cause, a correlate, or a consequence of therapeutic change following psychedelic administration?